The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 17, 2026

Filed:

Apr. 09, 2020
Applicant:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Inventors:

Christopher Daly, New York, NY (US);

Gavin Thurston, Briacliff Manor, NY (US);

Nicholas Papadopoulos, Woodlands, TX (US);

Assignee:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 25/00 (2006.01); A61P 25/04 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2863 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 25/00 (2018.01); A61P 25/04 (2018.01); A61P 29/00 (2018.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/74 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present invention provides fully human antibodies that bind to the RET receptor tyrosine kinase, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for treating diseases, disorders, or conditions associated with expression, activation, or signaling of the RET receptor tyrosine kinase gene, or a rearranged form thereof, including cancerous conditions and the pain associated with the cancer, or for alleviating the pain associated with other conditions attributed to, at least in part, by expression, activation or signaling of RET. The antibodies specific for RET may be useful for slowing tumor cell growth or tumor cell proliferation and also for alleviating the pain associated with the cancer and other conditions. The antibodies may also be useful for diagnosis of a disease, disorder or condition associated with RET activation or signaling.


Find Patent Forward Citations

Quick Actions:

Daly, Christopher. (2026). Human antibodies that bind ret and methods of use thereof (U.S. Patent No. 12799213). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12799213

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…